Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma

Clin Lymphoma Myeloma Leuk. 2023 Nov;23(11):857-860. doi: 10.1016/j.clml.2023.07.007. Epub 2023 Aug 1.

Authors

Affiliations

¹ Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address: dimad@ccf.org.
² Department of Internal Medicine, Cleveland Clinic, Cleveland, OH.
³ Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
⁴ Department of Hematology and Medical Oncology, Cleveland Clinic Florida, Maroone Cancer Center, Weston, FL.

PMID: 37558531
DOI: 10.1016/j.clml.2023.07.007

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / pharmacology
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Retreatment
Treatment Outcome

Substances

venetoclax
Bridged Bicyclo Compounds, Heterocyclic